09Mar 2020

STUDY OF SERUM BETA CATENIN LEVELS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

  • P.G. Student, Department of Biochemistry, Pt. B.D. Sharma PGIMS, Rohtak-12400, Haryana, India.
  • Senior Professor and Head, Department of Biochemistry, Pt. B.D. Sharma PGIMS, Rohtak-124001, Haryana, India.
  • Professor and Head, Clinical Hematology, Pt. B.D. Sharma PGIMS, Rohtak-12400, Haryana, India.
Crossref Cited-by Linking logo
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Introduction: Acute myeloid leukemia (AML) is a hematologic malignancy of the myeloid line of white blood cells in the bone marrow. Aim and Objectives: To estimate serum levels of beta catenin in AML patients and in age and sex matched healthy controls. Material and Methods: Twenty patients after confirmed diagnoses of acute myeloid leukemia were enrolled in the study. Diagnosis was based on blast cells 20% or more in peripheral blood smear/bone marrow by immunophenotyping (IPT)/flowcytometry. Twenty healthy age and sex matched volunteers served as controls. Results: The mean age for patients was 36.95?15.28. The beta catenin (pg/mL) levels were increased in male AML patients before chemotherapy (115.41?26.22) as compared to male controls (19.66?5.43) (p <0.001). Beta catenin levels were also increased in female AML patients before chemotherapy (114.25?22.55) as compared to female controls (19.37?4.53) (p <0.001). Nine male patients (45%) and 7 female patients (35%) achieved remission after induction chemotherapy while 3 male patients (15%) and 1 female patient (5%) failed to achieve remission. Conclusion: AML arise from a small pool of specialized leukemic stem cells (LSC), which have the idiosyncratic ability to self-renew. Targeted eradication of these stem cells will be crucial for permanent elimination of the disease and improved overall outcome. Wnt pathway controls self-renewal of hematopoietic stem cells (HSC) through regulation of beta catenin. Aberrant activation of beta catenin is a common event in AML and accumulating evidence indicates this pathway plays a critical role in the establishment and maintenance of myeloid neoplasms. Influencing this pathway seems to be a promising diagnostic and treatment strategy and should be followed up in further studies for future clinical use in patients with AML.


  1. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Edu Program 2004;204:80-97.
  2. Morin PJ. Beta-catenin signaling and cancer. BioEssays 1999;21:1021-30.
  3. Daniels DL, Spink KE, Weis W. [beta]-catenin: molecular plasticity and drug design. Trends Biochem Sci 2001;26:672-8.
  4. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
  5. Fodde R, Brabletz T. Wnt/[beta]-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-58.
  6. Falini B. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109-20.
  7. Dolled FM, McCabe A, Giltnane J, Creggar M, Camp RL. Quantitative in situ analysis of beta catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-94.
  8. Philip C, George B, Ganapule A, Korula A, Jain P, Abu AA, et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 2015;170:110-17.
  9. Preethi CR. Clinico-Hematological Study of Acutemyeloid Leukemias. J Clin Diag Res 2014;8:14-7.
  10. Mathur SK. Clinical profile of acute leukemias: A study of 50 cases: Indian Practitioner 1993;46:171-4.
  11. Gaydos LA, Freireich EJ, Mantel N. Нe quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905-9.
  12. Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt‐Wolf IG. Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 2009;144:796-8.
  13. Macheda ML, Stacker SA. Importance of Wnt signaling in the tumor stroma microenvironment. Curr Cancer Drug Targets 2008;8:454-65.
  14. Muller TC. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004;242890-4.
  15. Ysebaert L. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006;20:1211-6.
  16. Jamieson C, Johnson M, Molloy MP, Henderson BR. Specific armadillo repeat sequences facilitate b-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358. J Biol Chem 2012;287:819?831.
  17. Juan-Xaio X, Shen L, Yang YP, Zhu R, Shuai B, Li CG, et al.. Serum β-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis. Int J Endocrinol 2013.
  18. Kim Y, Reifenberger G, Lu D, Endo T, Carson DA, Gast SM. Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res 2011;31:725-30.
  19. Valencia A. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia, 2009.

[Neeraj Yadav, Veena Singh Ghalaut and Sudhir Kumar (2020); STUDY OF SERUM BETA CATENIN LEVELS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS Int. J. of Adv. Res. 8 (Mar). 188-194] (ISSN 2320-5407). www.journalijar.com


Dr. Neeraj Yadav
Department of Biochemistry Pt. B.D. Sharma PGIMS, Rohtak-124001 Haryana (India)

DOI:


Article DOI: 10.21474/IJAR01/10615      
DOI URL: http://dx.doi.org/10.21474/IJAR01/10615